Validated Technology Platform
VAXIMM’s core technology uses a genetically modified eukaryotic vector as a carrier of genetic sequences designed to specifically target key antigens to activate the host immune system.
This engineered eukaryotic vector (Ty21a), originally known as Vivotif™, serves as a highly effective delivery vector with an extensive safety profile as an approved oral vaccine against typhoid fever.
Priming and activating a systemic immune response via the Peyer’s patches in the gut allows for strong and persistent T-cell responses with a clinically proven safety profile suitable for continuous repeat administration. The safety and capability to generate a directed T cell response has been proven in prior clinical trials. This novel technology platform is specific yet versatile, with the potential to target multiple conditions with a single oral vector. In addition, combination treatment regimens have been clinically assessed with several immunotherapies. Several key advantages of this technology platform are highlighted:
- Robust T-cell response demonstrated against many different antigens in both pre-clinical animal models and in humans
- Safe therapeutic doses allow for continuous dosing regimens suitable for continuous prime and boost administrations without raising anti-carrier immunity and adding a significant safety margin
- Platform versatility enables addressing multiple targets with a single treatment and can be easily combined with other immunotherapies
- Rapid & efficient platform offers high modularity (‘plug and play’) capability, low-cost and robust production process, and rapid development timelines from concept to the clinical stage
Unique Mechanism of Action
Leveraging the gut’s intrinsic immune system to drive a targeted systemic response.
- Oral Administration & Gastric Transit – The genetically modified Ty21a vector is administered orally.
- Targeting of Gut-Associated Lymphoid Tissue (GALT) – The eukaryotic vector targets the Peyer’s patches in the small intestine, where specialized cells transport it into the body’s underlying immune tissue.
- Antigen Processing and Presentation – In the gut’s immune tissue, the vector is absorbed by Antigen-Presenting Cells (APCs). Inside, It releases a genetic payload that drives these cells to manufacture and present the specific target.
- T-Cell Priming and Activation – This initiates an adaptive immune response, leading to the robust activation and clonal expansion of both antigen-specific CD8⁺ cytotoxic T lymphocytes and CD4⁺ helper T-cells.
- Systemic Effector Response – The activated T-cells then enter systemic circulation, where they traffic throughout the body to locate and eliminate any malignant cells presenting the specific target antigen.